Abstracts Archive - Page 1641 of 2425 - ACR Meeting Abstracts

Abstract Number: 2534 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Allergic Conditions in Children Born to Women with SLE
Julie Couture¹, Moshe Ben-Shoshan¹, Christian A. Pineau², Susan Scott³, Ann E. Clarke⁴, Sasha Bernatsky² and Evelyne Vinet², ¹McGill University Health Centre, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Allergic conditions seem to be more prevalent in patients with SLE than in the general population. To date, a handful of small observational studies…
Abstract Number: 2535 • 2015 ACR/ARHP Annual Meeting
Increased Direct Healthcare Costs in SLE Pregnancies
Cristiano Moura¹, Sasha Bernatsky², Yvan St. Pierre³, Susan Scott³, Christian A. Pineau⁴, Ann E. Clarke⁵ and Evelyne Vinet⁴, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Although adverse obstetrical complications are more frequent in SLE women, no one has evaluated healthcare costs during SLE pregnancies. Thus, we aimed to evaluate…
Abstract Number: 2536 • 2015 ACR/ARHP Annual Meeting
The Role of Race/Ethnicity and SES in Adverse Pregnancy Outcome in SLE and Apl
Sancia Ferguson¹, Elianna Kaplowitz², Laura Trupin³, Edward H. Yelin⁴, Patricia P. Katz^3,5 and Jane E. Salmon⁶, ¹Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ²Hospital for Special Surgery, New York, NY, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, UC San Francisco, San Francisco, CA, ⁵Arthritis Research Group, University of California San Francisco, San Francisco, CA, ⁶Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) and Anti-Phospholipid Antibodies (aPL) have pregnancies with higher rates of preterm labor, preeclampsia, and fetal loss than healthy…
Abstract Number: 2537 • 2015 ACR/ARHP Annual Meeting
Prescription Medication Use in Sweden Among Pregnant Women with Systemic Lupus Erythematosus and General Population Comparators
Kristin Palmsten¹, Julia F Simard^2,3, Christina D Chambers^1,4 and Elizabeth V Arkema⁵, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁵Department of Medicine, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: There is limited information regarding medication use patterns among pregnant women with systemic lupus erythematosus (SLE). We aimed to characterize trends of medications used…
Abstract Number: 2538 • 2015 ACR/ARHP Annual Meeting
A Population-Based Assessment of Induced Abortions in Women with Systemic Lupus Erythematosus
Evelyne Vinet¹, Emily McDonald², Susan Scott³, Christian A. Pineau¹ and Sasha Bernatsky⁴, ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: SLE women with unplanned pregnancies might be at increased risk of both disease and pregnancy complications. Until now, there has been no population-based estimate…
Abstract Number: 2539 • 2015 ACR/ARHP Annual Meeting
The Validity and Reliability of Turkish Version of the Jenkins Sleep Scale in Rheumatoid Arthritis
M Tuncay Duruoz¹, Cagri Ünal², Firat Ulutatar³, Canan Sanal Top² and Osman Hakan Gunduz⁴, ¹Dept of PM&R, Rheumatology Clinic, Marmara University Medical School, Istanbul, Turkey, ²PM&R, Marmara University Medical School, Istanbul, Turkey, ³Physical Medicine and Rehabilitation Department, Marmara University Medical School, Istanbul, Turkey, ⁴Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: The Jenkins Sleep Scale has 4 questions to assess the estimation of sleep problems in clinical research. It was developed in USA (1). Aim: To…
Abstract Number: 2540 • 2015 ACR/ARHP Annual Meeting
Construct Validity of the Promis-29 in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort
Linda Kwakkenbos¹, Brett D. Thombs¹, Susan J. Bartlett², Marie-Eve Carrier³, Marie Hudson¹, Luc Mouthon⁴, Vanessa L. Malcarne⁵, Maureen Sauvé⁶, Dinesh Khanna⁷ and SPIN investigators, ¹McGill University, Montreal, QC, Canada, ²Medicine, McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ⁴Paris Descartes University, UPRES-EA 4058, Department of Internal Medicine, Cochin Hospital, Paris, France, ⁵SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ⁶Scleroderma Societies of Canada and Ontario, Hamilton, QC, Canada, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS¨) initiative is a cooperative research program designed to develop, evaluate, and standardize item banks to measure patient-reported…
Abstract Number: 2541 • 2015 ACR/ARHP Annual Meeting
Improving Adherence with Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Rationale and Design of the Traction Trial
Daniel H. Solomon¹, Sara Lee², Agnes Zak², Jen Agosti³, Asaf Bitton⁴, Liana Fraenkel⁵, Leslie Harrold⁶, Elena Losina⁷, Bing Lu⁸, Theodore Pincus⁹, Josef S. Smolen¹⁰ and Jeffrey N. Katz¹¹, ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³JRA Consulting, Andover, MA, ⁴Medicine, Brigham and Women's Hospital, Boston, MA, ⁵Medicine, Yale University School of Medicine, New Haven, CT, ⁶Dept of Medicine, UMass Medical School, Worcester, MA, ⁷Orthopedics, Brigham and Women's Hospital, BU School of Public Health and Harvard Medical School, Boston, MA, ⁸Rheumatology Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁹Medicine-Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Treat to target (TTT) is a recommended paradigm in the management of rheumatoid arthritis (RA). However, various data sources suggest that TTT is…
Abstract Number: 2542 • 2015 ACR/ARHP Annual Meeting
The Multidimensional Assessment of Fatigue Scale: A 25-Year Review and Evaluation
Basia Belza¹, Christina Miyawaki^2,3, Minhui Liu¹, Xi Zhang⁴ and Melissa Fessel¹, ¹University of Washington School of Nursing, Seattle, WA, ²University of Houston Graduate College of Social Work, Houston, TX, ³Group Health Research Institute, Seattle, WA, ⁴Henan Provincial People's Hospital, Zhengzhou, China
Background/Purpose: The Multidimensional Assessment of Fatigue (MAF) scale was originally developed in 1990 for adults with rheumatoid arthritis. Since then, the MAF has been translated…
Abstract Number: 2543 • 2015 ACR/ARHP Annual Meeting
Content Validity of the Improved Health Assessment Questionnaire in Knee Osteoarthritis Patients
Mei Chung¹, Shanshan Liu², Zhuxuan Fu², Lori Lyn Price³, John B. Wong⁴ and Chenchen Wang⁵, ¹Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, ²Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, ³Clinical Care Research, Tufts Medical Center, Boston, MA, ⁴Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, ⁵Rheumatology, Tufts Medical Center, Bosotn, MA
Background/Purpose: Developed in general population, rheumatoid arthritis and osteoarthritis patients, the Improved Health Assessment Questionnaire (iHAQ, formerly PROMIS HAQ) assesses physical function. The objective of…
Abstract Number: 2544 • 2015 ACR/ARHP Annual Meeting
Representing the Variability in Patients’ Preferences
Raluca Cozmuta¹, Sonal Bhalla² and Liana Fraenkel³, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Medicine, Yale University School of Medicine, New Haven, CT
Background/Purpose: Data describing patients' priorities, concerns, and preferences are essential to inform important decisions in health care, including treatment planning and the development of programs…
Abstract Number: 2545 • 2015 ACR/ARHP Annual Meeting
Psychometric Testing of the Valued Life Activities Questionnaire in People with Rheumatoid Arthritis in the UK: Rasch Analysis
Yeliz Prior¹, Alan Tennant² and Alison Hammond³, ¹Centre for Health Sciences, University of Salford, Greater Manchester, United Kingdom, ²Human Functioning Sciences, ICF Unit, Swiss Paraplegic Research, Nottwil, Switzerland, ³Centre for Health Sport & Rehabilitation Research, University of Salford, Salford, United Kingdom
Background/Purpose: Developed in the USA, the Valued Life Activities Scale (VLAs) measures participation in daily activities. We have linguistically and culturally adopted the VLAs 33…
Abstract Number: 2546 • 2015 ACR/ARHP Annual Meeting
Targeting Synovial Fibroblasts By the Intra-Articular Delivery of microRNA-140-3p and -5p Ameliorates Experimental Autoimmune Arthritis
Chrong-Reen Wang¹, Jia-Shiou Peng², Shih-Yao Chen³, Chao-Liang Wu⁴ and Ai-Li Shiau⁵, ¹Rheum/Immun Sec/Int Med Dept, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ²Institute of Basic Medical Sciences, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ³Internal Medicine, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁴Biochemistry and Molecular Biology, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan, ⁵Microbiology and Immunology, College of Medicine, National Cheng Kung University, Medical Coll/Nat'l Cheng Kung, Tainan, Taiwan
Background/Purpose: Synovial fibroblasts (SF) with aberrant expression of microRNAs (miRNA) are critical pathogenic regulators of rheumatoid joint, and studies examining the effect of overexpressing or…
Abstract Number: 2547 • 2015 ACR/ARHP Annual Meeting
NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis
Yuuki Hidaka¹, Takanori Nakamura², Tadashi Igarashi², Takeshi Nanya², Shuhei Hagiwara², Kazuya Takeuchi², Tomonori Yaguchi³, Yutaka Kawakami³ and Takeshi Naito², ¹Pharmaceutical Research Department, Nissan Chemical Industries,LTD., Saitama, Japan, ²Nissan Chemical Industries,LTD., Saitama, Japan, ³Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Non-selective Janus kinase (JAK) inhibitors have shown long-term efficacy in treating rheumatoid arthritis (RA). However, clinical efficacy is limited due to concerns of dose-limiting…
Abstract Number: 2548 • 2015 ACR/ARHP Annual Meeting
M-CSF-R Is a Critical Determinant for the Differentiation of Classical to Non-Classical Monocytes
Philip J. Homan¹, Alexander Misharin¹, Carla Cuda², Salina Dominguez², Rana Saber², Fu-Nien Tsai³ and Harris R. Perlman⁴, ¹Medicine-Rheumatology, Northwestern University, Chicago, IL, ²Northwestern University, Chicago, IL, ³Medicine, Rhuematology, Northwestern University, Chicago, IL, ⁴Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Colony-stimulating factors (CSF) are simply defined as haemotopoitec growth factors. However, CSFs have been implicated to have additional functions in various autoimmune diseases. Specifically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].